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Abstract
Inflammation is a multifaceted process: beneficial as a defense mechanism but also detrimental depending on its severity
and duration. At the site of injury, inflammatory cells are activated by a cascade of mediators, one of which is LITAF, a
transcription regulator known to upregulate TNF-a. We previously showed that human LITAF forms a complex with human
STAT6B, which translocates into the nucleus to upregulate cytokine transcription. To dissect the molecular implications of
this complex, a murine model was developed and interactions between mouse STAT6B (mSTAT6B) and mouse LITAF
(mLITAF) were analyzed. Both mLITAF and mSTAT6B expression were MyD88- and TLR ligand-dependent. Furthermore,
mLITAF was found to mediate LPS-induced CCL2 gene transcription with the cooperation of mSTAT6B leading to CCL2
protein expression. In LITAF-deficient mice, mLITAF-mediated CCL2 production in macrophages was significantly reduced
compared to the wild-type control animals. Mice knockdown for mSTAT6B by 6BsiRNA1 tail vein injection resulted in a
decrease in serum TNF-a and CCL2 production. mLITAF/mSTAT6B complex is proposed to play a role in LPS-induced CCL2
expression and possibly other cytokines.
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Introduction
The inflammatory response is the body’s defense mechanism
against harmful stimuli or damage. However, abnormal and
prolonged inflammatory reactions can be detrimental and are
related to immune system disorders [1,2], atherosclerosis [3,4],
arthritis [5,6], heart diseases [7,8] and cancer [9,10]. At the site of
injury, a cascade of mediators, including cytokines (e.g. TNF-a, IL-
1, IL-6 and CCL2), eicosanoids and reactive oxygen intermedi-
ates, activate nearby inflammatory cells such as macrophages and
granulocytes, and promote additional leukocytes to extravagate
from blood vessels and to infiltrate the surrounding tissues. CCL2,
also known as monocyte chemoattractant protein-1 (MCP-1), is a
chemokine associated with cerebral ischemia and rheumatoid
arthritis [1], insulin resistance [11] and prostate cancer [2]. As
cytokine or chemokine dysregulation has been implicated in
inflammatory diseases, it is important to establish the manner in
which chemokine or cytokine gene expression is controlled, thus
providing potential therapeutic intervention in these diseases [3].
It is known that transcription factors must translocate into the
nucleus using a nuclear core complex (NPC) to achieve gene
transcription. We previously cloned and characterized a tran-
scription factor that we named LPS-Induced TNF-Alpha Factor
(LITAF) [12]. The cytoplasm-nucleus shuttling of LITAF
sequentially enhances the transcription of the tumor necrosis
factor-alpha (TNF-a) [13]. Proteins like LITAF contain a nuclear
localization signal(s) (NLS) that facilitates translocation into the
nucleus [14].
The present study confirms that just like in human [13,15], both
mouse LITAF (mLITAF) and mouse STAT6B (mSTAT6B)
expression were MyD88- and TLR ligand-dependent. In addition
LPS-induced mSTAT6B directly interacts with mLITAF and
forms a complex in cytoplasm. This complex then translocates into
the nucleus, where it upregulates the transcription of several
inflammatory cytokines. Finally, p38a MAP kinase was found to
mediate mLITAF gene expression and inhibition of p38a blocked
LITAF nuclear translocation.
Building on these data, we further demonstrate that the
knockdown of mSTAT6B by 6BsiRNA1 prevented mLITAF
from regulating CCL2 production but mSTAT6B does not play a
role in regulation of CCL2 production in the absence of mLITAF.
Tail vein injection of 6BsiRNA1 in mice resulted in the reduction
of LPS-induced serum TNF-a or CCL2 levels in mice. The
present data implicate mLITAF/mSTAT6B complex in LPS-
induced TNF-a and CCL2 expression and discuses the potential
role of this complex in other cytokine gene expression for the
control of inflammatory processes.
Materials and Methods
Animals, cell lines, and bacteria
Wild-type and genotype deficient C57BL-6 mice (TLR-2
2/2
Cat# 004650, TLR-4
2/2 Cat# 007227-9, or MyD88
2/2
Cat#009088) were purchased from The Jackson Laboratory.
The mLITAF conditional knockout mouse strain (macLITAF
2/2)
was generated by our laboratory as described previously [15]. All
mice protocols used in this study have been approved by Boston
University Animal Care and Use Committee. Mouse peritoneal
macrophages were elutriated from wild type and genotype
deficient mice (LITIF
2/2), and purified by conventional methods
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supplied by ATCC. All bacterial cloning constructs used were E.
coli strain DH5a (Invitrogen, Carlsbad, CA). Strain 381 of P.
gingivalis was grown in brain heart infusion broth with hemin
(5 mg/ml) and menadione (1 mg/ml) in an anaerobic atmosphere
(85% N2/10% H2/5% CO2) for 24–48 h at 37uC before
preparation of LPS as we have described [16].
Mice and tail vein injection
Age and weight-matched wild-type mice (C57BL/6) were
selected and treated with tail vein injection [5] with E.coli LPS
and/or RNAi (Table 1). Following the injection, serum TNF-a
concentration from each mouse was measured by ELISA and mice
were monitored for up to 72 hrs.
Design of siRNAs
Two siRNA sequences, 6BsiRNA1: 59-GATGTCACTCCC-
TATTTCATA-39 for silencing mSTAT6B gene expression, and
6BsiRNA2: 59-GAGCACTCCATGGCTGTCTTT-39 as the
negative control were designed by a commercial software (www.
sirnawizard.com/design_advanced.php). Their RNA sense strand
and antisense strand were synthesized (Qiagen) and used for
promoter assay and ELISA as described below.
Plasmid DNA constructs
(1). The mouse LITAF DNA (mLITAF) fragment subcloned
into the pCDNA3HA [13] vector were obtained by our
laboratory.
(2). The mouse mSTAT6B in-frame DNA fragment
(bankit1369793; submitted to GenBank) was generated by PCR
reaction with primer pairs: 59-ATGGCCCGAC GGAACCCT-
TC-39 and 59-GTCATCTTGATGGTAGCT-39 and subcloned
into the pcDNA3HA and named mSTAT6B.
(3). The mouse CCL2 59UTR&promoter (Genebank Access#
NT-096135, 21034 to +1 bp relative to the ATG start codon)
sequences were selected. Five DNA constructs with CCL2
59UTR&promoter sequential deletions were generated and
amplified by PCR with a same reverse primer: 59-TGGTG-
GTGGAGGAAGAGA-39 and five diversified forward primers: 1)
59-ACGAAGGAAACAGGGCAGAG-39 for mCL2Pwt (21034,
+1 bps), 2) 59-TGACCCTTCT GGACCTCAGC-39 for mCL2P840
(2840,+1 bps), 3) 59-TATTCAACAAGGCCTGATAA-39 for
mCL2P560 (2560,+1 bps), 4) 59-TTCCTTTTATTTCAGTGAA-
A-39 for mCL2P420 (2420,+1b p s ) , a n d 5 ) 5 9-AAAATACCA-
AATTCCAACCC-39 for mCL2P280 (2280,+1b p s ) . T h e
individual PCR products of CCL2-59UTR&promoter (1034 bps,
840 bps, 560 bps, 420 bps and 280 bps) were subcloned into the
luciferase reporter vector, pGL3-basic.
(4). The DNA fragments of 59UTR&Promoter of CCL1(AL
713839), IL-1b( NT_039207.7), IL-6 (NT_162294.3), and IL-
10(HQ014592) were generated by PCR with mouse genomic DNA
(obtained from our lab) as template and primer pairs 59-tagaca-
gacaggatcaacct-39&59-ggtgataagtttctgtctca-39,5 9-aagtgcgtgtctctcca-
gaa-39&59-agctgcttcagacacctg-39,5 9-ctccttgcatgacctggaaa-39&59-a-
gcggtttctggaattgact-3, and 59-cttgcccagggtacagaa-39&59-gatggagc-
tctcttttct-39. The individual PCR products of 59UTR&promoter
(named CCL1-p, IL-1b-p, IL-6-p, or IL-10-p) were subcloned into
the luciferase reporter vector, pGL3-basic.
Preparation of protein extracts and Western blot analysis
The cell lysate from mouse primary macrophages were
subjected to SDS-PAGE and transferred to a membrane then
blotted with antibodies against mouse mSTAT6B (5278, BioSyn-
thesis, Inc), LITAF (Cat #611614, BD Biosciences), NF-kB p65
(RelA, sc-372), CSF-1 (LS-C104794-50, BioSciences) or Actin as
control for Western blot analysis.
ELISA
The conditioned media from Mouse Raw 264.7 cells or mouse
primary macrophages or plasma samples from mice were
subjected to ELISA for detection of endogenous expression of
MCP-1 (CCL2, Invitrogen), TNF-a (Invitrogen), MCP-2 (bio-
compare), IL-1a (Invitrogen), IL-1b (Invitrogen), IL-6 (Invitrogen),
IL-10 (Invitrogen), or RANTES (Invitrogen). Total protein
concentration of corresponding cell lysate was measured and used
for normalization.
Luciferase assay
Mouse Raw 264.7 (1610
6) cells were transiently transfected/
cotransfected with appropriate promoter-reporter DNA alone
such as mCL2Pwt, mCL2P840, mCL2P560, mCL2P420, and
mCL2P280, and/or plus mSTAT6B, mLITAF, both mSTAT6B/
mLITAF or pcDNA3 as control by LipofectAMINE 2000
(Invitrogen Cat#11668019). The luciferase activity from the
treated cells was quantified with a Turner Designs luminometer
model TD-20/20 by reaction of the appropriate transfected cell
lysate 1:1 (vol/vol) with the substrate solution (Cat#E151A,
Promega). Triplicate assays were performed and the data was
analyzed. Values were normalized to b-gal production and
graphed.
Table 1. Tail vein injection of E.coli LPS plus 6BsiRNA1 or 6BsiRNA2 as the control.
No. of group
(6mice/group)
Tail vein
injection
Untreated 1 mg LPS/mouse 40 uM m6BsiRNA2/mouse 20 uM m6BsiRNA1/mouse 40 uM m6BsiRNA1/mouse
1 +
2 +
3 +
4 +
5 ++
6 ++
7 + +
doi:10.1371/journal.pone.0025083.t001
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RAW264.7 murine macrophages grown in RPMI medium
1640 with 10% FBS were transfected with mLITAF or mSTAT6B
for 24 h. Cells were rinsed once with ice-cold PBS and routinely
lysed in the lysis buffer (Promega) supplemented with protease
inhibitors. Lysates were precleared by pre-incubation with protein
A/G-agarose-Sepharose beads (Cat #sc-2003, Santa Cruz
Biotechnology) for 30 min, and incubated at 4uC for 2 h with
2 mg of HA antibody, followed by addition of 20 ml of protein A/G
plus-agarose-Sepharose beads for another hour. The beads were
washed three times in PBS then the immune complexes were
released from the beads by boiling in SDS sample buffer for 5 min.
Immunoprecipitated products were analyzed by EMSA.
Chromatin Immunoprecipitation (ChIP)
Experiments were performed using a commercial kit (Cat#:
53009, ChIP-IT Express Enzymatic, Active Motif) with some
modifications. 1610
6 Raw 264.7 cells were transfected with 1 mg
of mLITAF DNA or 1 mg of mSTAT6B DNA overnight. The
10 mg nuclear extracts (NE) as input from the cross-linked cells
were immunoprecipitated (IP) with 1 mg LITAF antibody, 1 mg
5278 (anti-mSTAT6B) antibody or 1 mg normal IgG as control at
4uC for 4 hrs. DNAs from each experimental group (input or IP)
were isolated by elution, reverse cross-linking and Proteinase K
treatment according to the manufacturer’s instruction. The DNA
was then used as template to perform PCR with primer pairs
(A+B, C+D, E+F, G+H, G+I, or I+J for amplification of DNA
fragment of CCL2 59UTR&promoter by PCR. GAPDH primer
pairs (Invitrogen) as control was used at the same condition.
EMSA
A commercial kit, Gel Shift Assay System (Promega), was used.
A reaction mixture contained 2 mL of HeLa nuclear extract,
1610
5 cpm/mL radiolabeled double-stranded oligo DNA probe,
an appropriate concentration of E. coli protein extraction, HA-
Immunoprecipitated protein (IP-mLITAF or IP-mSTAT6B), 2 mL
of 56 reaction buffer, and nuclease-free water to achieve a final
volume of 10 mL. Mixtures were incubated at room temperature
for 20 min, followed by electrophoresis on nondenaturing 6%
polyacrylamide gels in Tris-borate-EDTA buffer (90 mM Tris-
borate, 2 mM EDTA and HEPES, at pH 8.0). The gel imaging
was developed.
Statistical analysis
The SAS software package was used for all statistical analyses.
All experiments were performed at least in triplicate. All the data
were normally distributed. In case of multiple mean comparisons,
data were analyzed by analysis of variance (ANOVA). In case of
single mean comparison, data were analyzed by Student’s t-test. In
case of time-course study, data were analyzed by two-way repeated
measure ANOVA, and P values less than 0.05 were regarded as
significant.
Results
TLR involvement in mLITAF/mSTAT6B signaling pathway
To determine TLR engagement in mLITAF/mSTAT6B
signaling, mLITAF or mSTAT6B protein levels in response to
LPS stimulation in mouse macrophages of various genotypes
(TLR-2
2/2,- 4
2/2,- 9
2/2, MyD88
2/2, and wildtype as control)
were measured by Western blot. As shown in Fig. 1a, both
mSTAT6B and mLITAF were induced by either P. gingivalis or E.
coli LPS in TLR-9
2/2 macrophages (No. 3&4) but not induced at
all in MyD88
2/2 macrophages (No. 9&10). This implied that
TLR-9 was not involved in LPS-signaling pathway, while MyD88
is required for signal transmission and thus the pathways are
myD88 dependent. In TLR-4
2/2 macrophages, mSTAT6B and
mLITAF were induced by P. gingivalis LPS (TLR-2 ligand) (No. 5)
but not by E. coli LPS (TLR-4 ligand) (No. 6), while in TLR-2
2/2
macrophages, mSTAT6B and mLITAF were induced by E. coli
LPS (No. 8) but not by P. gingivalis LPS (No. 7) compared to
control. These findings indicate that mLITAF and mSTAT6B
induction occurred with either TLR-2 or TLR-4 engagement.
Nuclear translocation of mLITAF with mSTAT6B as a
complex
Analysis of the mSTAT6B sequence discloses only partial
homology to human STAT6B and no homology to human
STAT6 advocating for the existence of 3 distinct genes (See
Information S1 and Figure S1). Either E.coli or P.g. LPS are
capable of inducing mSTAT6B independently from mLITAF (See
Information S1, and Figure S2). The pull-down assay showed that
mLITAF associates with mSTAT6B via protein-protein interac-
tion in response to LPS (See Information S1 and Figure S2b).
Finally, phosphorylation of p38 kinase was involved in LPS/
TLR2-4/mLITAF/mSTAT6B signaling pathway (See Informa-
tion S1 and Figure S3) similar to human LITAF/STAT6B-
dependent signaling pathway [13,15].
To dissect the mechanism associated with the mLITAF/
mSTAT6B complex formation and its nuclear translocation,
mouse macrophage were transfected with mLITAF and/or
mSTAT6B (Fig. 1b). Overexpression of either mLITAF alone
(Fig. 1b, No. 3) or mSTAT6B alone (No. 4) did not yield a protein
band in the nuclear lysate as compared to controls (No. 1&2).
However, overexpression of both mLITAF and mSTAT6B
(No. 5) produced a detectable band in the nucleus, indicating
that nuclear translocation of these proteins were dependent on the
formation of mLITAF/mSTAT6B complex. To further determine
the dependence between mLITAF and mSTAT6B in macro-
phages for their nuclear translocation in response to LPS
stimulation, the nuclear or cytoplasmic lysate from E. coli LPS-
treated mouse macrophages of wild-type (Fig. 1c, No. 1&2) or
LITAF knock-out (No. 3&4) mice were detected by LITAF or
5278. As shown in Fig. 1c, neither mLITAF nor mSTAT6B
protein was observed in the nuclear lysate (No. 4) even though a
good protein yield of mSTAT6B remained in the cytoplasm
(No. 4) compared with controls. This suggests that mSTAT6B is
LITAF-dependent and not able to translocate into nucleus in the
absence of LITAF.
The role of mLITAF/mSTAT6B in regulation of CCL2 gene
expression
To examine the biological function of mLITAF/mSTAT6B
complex, a promoter assay was performed. As shown in Fig. 2a,
overexpression of both mLITAF and mSTAT6B significantly
increased CCL2 promoter activity. To define whether there is a
consensus sequence for the binding of mLITAF to cytokine
promoters, CCL2 and other cytokines. In order to determine the
binding activity of mLITAF and mSTAT6B to CCL2 59UTR&-
promoter, PCR primer pairs (A–J) were designed covering the
CCL2 59UTR&promoter region (Fig. 2b&c) and chromatin
immunoprecipitation (ChIP) was further performed. As shown in
Fig. 2d, the DNA fragment of CCL2 59UTR&promoter was
amplified by PCR with IP-mLITAF and primer pairs (G&H or
G&J) but not detected with primer pairs (A&B, C&D, E&F or I&J).
This suggests that the region from 2420 to 2280 of CCL2
59UTR&promoter contains a binding site for LITAF interaction.
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with all primer pairs for IP-mSTAT6B, indicating that mSTAT6B
does not directly interact with CCL2 59UTR&promoter. The
binding site of 2420 to 2280 was further confirmed by EMSA. As
shown in Fig. 2e, the [
32P]ATP-labeled double-stranded nucleo-
tide 2400 to 2300 of CCL2 59UTR&promoter was treated with
IP-mSTAT6B or IP-mLITAF fusion proteins or E. coli protein
extraction as control. The shifted DNA bands as indicated by
arrows were observed with IP-mLITAF (Fig. 2e, No. 6-8) but not
IP-mSTAT6B (No. 5) compared to the control (No. 4). These
findings suggest that mLITAF functions as a binding factor in the
regulation of CCL2 gene expression.
To determine whether the CTCCC sequence identified for the
binding of mLITAF on TNF promoter was present in CCL2 as
well as other mediators, bioinformatics analysis of the promoter
sequences for some inflammatory mediators was performed. We
found that TNF-a, CCL2 (MCP-1), MCP-2, IL-1a, IL-10, and
RANTES which promoter contained a ‘‘CTCCC’’ sequence
responded to LITAF-mediated stimulation. Consistent with this
finding, cytokine promoters lacking a CTCCC sequence upstream
of the transcription initiation site, such as IL-6 or IL-1b were not
affected by LITAF (Table 2).
To determine whether CCL2 promoter activity is dependent on
mLITAF binding activity alone, CCL2 59UTR&promoter report-
er DNA deletions were constructed (Fig. 3a). This approach
allowed us to also determine the location of the biding activity. As
shown in Fig. 3b, transfection of mLITAF alone (yellow bars) or
both mLITAF&mSTAT6B (blue bars) caused between 2 to 2.5
fold upregulation of CCL2 promoter activity while transfection of
mSTAT6B alone (pink bar) did not have any activity promoter.
This upregulated activity was maintained even until the 59UTR&-
promoter region lacked the 59UTR&promoter region from
21,134 to 2420 and was lost when the region lacked from
21,134 to 2280 suggesting that the critical binding activity was
Figure 1. mSTAT6B/mLITAF signaling pathway. (a) The primary macrophages collected from various deficient genotype mice (No. 1&2 and
11&12 for wild-type as the control, No. 3&4 for TLR-9
2/2, No. 5&6 for TLR-4
2/2, No. 7&8 for TLR-2
2/2, or No. 9&10 for MyD88
2/2) were treated with
0.1 mg/ml P. gingivalis LPS (No. 3,5,7,9&11) or 0.1 mg/ml E. coli LPS (No. 4,6,8,10&12) for 2 hrs and washed with PBS and cultured overnight. The cell
lysate from each test group was subjected to Western blot with antibodies against mSTAT6B (5278), mLITAF or Actin as the control. The assays were
performed in triplicate and a representative experiment is presented. (b) Mouse macrophages were transfected with either mLITAF alone or mSTAT6B
alone or cotransfected with both mLITAF and mSTAT6B. Proteins from cytoplasm and nucleus of cells were purified separately and subjected to
Western blot analysis using antibodies against mLITAF, mSTAT6B (5287), or Actin (control) as indicated by arrows. The assays were performed in
triplicate and a representative experiment is presented. The protein band intensity was analyzed using VersaDoc Imaging System model 4000 MP
with Quantity One Quantitation Software version 4.6.3 (Bio-Rad). The band intensity from cytoplasm of untreated cells was used as control and
assigned 100%. The other bands were evaluated compared to the control and their intensities with % were attached. (c) Mouse macrophages
collected from wild-type mouse (No. 1&2) or from LITAF-deficient genotype mice (No. 3&4) were treated with 0.1 mg/ml E.coli LPS (No. 2&4) or
untreated as control (No. 1&3) for 2 hrs and washed with PBS and cultured overnight. Proteins from cytoplasm and nucleus of treated cells were
purified separately and subjected to Western blot with the antibodies against mLITAF, mSTAT6B (5287), or Actin as control (indicated by arrows). The
assays were performed in triplicate and the representative experiment a shown.
doi:10.1371/journal.pone.0025083.g001
Regulation of CCL2 Gene Expression
PLoS ONE | www.plosone.org 4 September 2011 | Volume 6 | Issue 9 | e25083located between 2420 and 2280 59UTR&promoter sequence.
Furthermore, a dose course promoter assay was performed to
show that an increasing concentration of mSTAT6B enhanced
CCL2 promoter activity (Fig. 4a, No. 7-9). Consequently,
knockdown of mSTAT6B using 6BsiRNA1 reduced CCL2
promoter activity to 68% (No. 10) and 29.2% (No. 11) in
comparison to the effect of 100 ng of mSTAT6B alone as the
100% baseline (No. 9), while no significant reduction was observed
with control 6BsiRNA2 (No. 12&13). To confirm this regulation at
the protein level, Raw264.7 cells were transfected with mLITAF
Figure 2. mSTAT6B and/or mLITAF-mediated cytokine promoter activities. (a) Raw264.7 cells were untreated as control (green bars) and
transiently transfected with reporter genes of CCL1-p, CCL2-p, IL-1b-p, IL-6, or IL-10-p with the addition of pcDNA3 (white bars), mSTAT6B (pink bars),
mLITAF (yellow bars), or both mSTAT6B and mLITAF (blue bars). All test cells were cotransfected with 5 ng of b-gal DNA. Cell lysate was then purified
and examined by luciferase assay. Triplicate assays were performed and their values were normalized to b-gal production and graphed. (b) Diagram
of mouse CCL2 59UTR&promoter DNA sequence in the region from 21,034 to 1. The putative mLITAF binding site (CTCCC) in the region
(2319,2315, 2298,2294) is underlined. (c) Diagram of primer (A–J) location in mouse CCL2 59UTR&promoter DNA and their size. (d) CHIP assay.
DNAs from input group as control or CHIP group (LITAF or 5279) were used for PCR with primer pairs of A&B, C&D, E&F, G&H, G&J, or I&J. The control
(input) group showed DNA fragments that were amplified by PCR with all primer pairs. Fragments amplified by PCR with primer pairs G&H or G&J
were shown only in the LITAF CHIP group. None of the PCR-amplified DNA fragments in mSTAT6B (5278) CHIP group were observed. The assays were
performed in triplicate and a representative experiment is presented. (e) EMSA. HA-immunoprecipitated protein (IP) from each test cells was purified
and added to the appropriate reaction buffer with the 32p-ATP-labeled double stranded CCL2 oligonucleotide (GCAGAGCCACTCCATTCA-
CACTTGTGGTCACAGTAGTACAAT TACTGCCAATTCTTCCCTCTTTCCCCCCCCCCCCCCCTACTCCCTGCGCAGCTTCATTT) as DNA probe. Treatment with
DNA probe alone in No. 1 and 3, with 100-fold excess of unlabeled competitor (No. 2), or plus 1 mgo fE. coli extraction as control (No. 4), 1 mg IP-
mSTAT6B (No. 5), different concentration of IP-mLITAF (0.25 mg in No. 6, 0.5 mg in No. 7, 1 mg in No. 8) were assessed by EMSA. The shifted bands are
indicated by arrow. The assays were performed in triplicate and a representative experiment is presented.
doi:10.1371/journal.pone.0025083.g002
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mSTAT6B plus 6BsiRNA1 or 6BsiRNA2 as control. As shown
in Fig. 4b, transfection with mLITAF/mSTAT6B caused a high
CCL2 production in Raw264.7 cells, while knockdown of
mSTAT6B by 6BsiRNA1 reduced CCL2 protein level to 38%
(No. 5) in comparison to uninhibited mLITAF/mSTAT6B as the
100% baseline (No. 4). No significant reduction was observed with
control 6BsiRNA2 (No. 6). Finally, in order to examine how
endogenous mLITAF/mSTAT6B regulates CCL2 production,
wild type or LITAF
2/2 mouse primary macrophages were treated
with 6BsiRNA1 and 6BsiRNA2 as control after LPS stimulation.
The conditioned medium from each test group was assessed by
ELISA. As shown in Fig. 4c, treatment with 40 nM of 6BsiRNA1
reduced LPS-induced CCL2 production to 63.9% compared to
LPS alone as the 100% baseline in wild-type cells. However, no
effect was observed under the same condition in LITAF
2/2 cells.
These results suggested that 1) knock down of mSTAT6B
prevented mLITAF from regulating CCL2 production and 2)
mSTAT6B did not play a role in regulation of CCL2 production
when mLITAF was knocked out.
In addition, as it is well known that CCL2 gene expression in
macrophages is upregulated by other factors such as RelA [17,18]
or CSF-1 [19] in response to LPS. Our investigation focused on
whether cell transfection of 6BsiRNA1 would affect these factors as
detected by Western blot anlaysis. As shown in Fig. 4d, RelA or
CSF-1 production was induced by LPS in either wild-type (No. 2)
or LITAF-deficient cells (No. 5). These LPS-induced proteins were
not significantly reduced in the presence of 6BsiRNA1 (No. 3&6),
whereas mSTAT6B production (5278) was reduced at the same
condition (No. 3 or 6). However, RelA or CSF-1 protein
translocation to nucleus was not affected by either mSTAT6B
gene expression (No. 2) or gene knocked down (No. 3) in response
to LPS (Fig. 4e).
Our previous study showed that LITAF-deficient macrophages
reduced LPS-induced TNF-a production [13,15] and data in this
study indicate that knockdown of mSTAT6B by 6BsiRNA1 in
macrophages decreased LPS-induced CCL2 production. There-
fore we were interested to determine whether i.v. injection of
6BsiRNA1 in mouse protects animal from LPS-induced TNFa/
CCL2 production. To address this, mice were treated as described
(Table 1) by tail vein injection with one of the following: PBS alone
(untreated, No. 1), 40 uM m6BsiRNA2 alone (No. 2), 40 uM
m6BsiRNA1 alone (No. 3) or LPS (No. 4) plus 40 uM
m6BsiRNA2 (No. 5) or plus 20 uM m6BsiRNA1 (No. 6) or plus
40 uM m6BsiRNA1 (No. 7) and monitored for up to 72 hr. Blood
from treated mouse was collected within 5 hrs of injection and the
serum levels of TNF-a, CCL2, IL-1b and IL-6 was determined by
ELISA. As shown in Fig. 5, the injection of LPS alone (positive
control) and/or m6BsiRNA2 (negative control) stimulated high
levels of serum TNF-a (Fig. 5a, No. 4&5) and CCL2 (Fig. 5b,
No. 4&5). However, LPS-induced TNF-a/CCL2 production in
the presence of m6BsiRNA1 was reduced by up to 37% (Fig. 5a&b,
No. 7) relative to the positive control. Additionally, LPS-induced
IL-1b or IL-6 production was not affected in the presence of
m6BsiRNA1 (Fig. 5c), suggesting that mSTAT6B does not
mediate IL-1b or IL-6 regulation. In order to analyze the effect
of m6BsiRNA1 on mSTAT6B expression, protein samples from
each experimental group were analyzed by Western blot using
antibodies against mSTAT6B, mLITAF and Actin. As shown in
Fig. 5a (Western blot, top panel), LPS-induced mSTAT6B
expression (No. 4) was significantly reduced in the presence of
m6BsiRNA1 (No. 6&7) compared to controls. Altogether, our
data show that mSTAT6B may be a important factor that
associates with mLITAF to form a complex which translocates into
the nucleus. The use of m6BsiRNA1 to inhibit mSTAT6B leads to
reduced mLITAF/mSTAT6B-mediated TNF or CCL2 levels in
response to LPS.
Discussion
In this study, we identified the mouse STAT6B gene and
characterized its translated protein. Upon LPS stimulation,
mLITAF nuclear entry is facilitated by its association with
mSTAT6B and the formation of this mSTAT6B/mLITAF
complex is crucial for nuclear tranlocation. This translocation
leads to TNF and/or CCL2 production as evidenced in our LPS
animal model and prevented in LITAF-deficient animals or by
using siRNA directed against mSTAT6B.
Based on the present data (See Information S1 and Figure S1),
mSTAT6B is highly homologous to human STAT6B [13], but
different from human STAT6 [20]. We believe that the C-
terminal truncation of mSTAT6B could be resulting from two
possible mechanisms: 1) an alternative mRNA splicing product
from a single gene and/or 2) proteolytic processing which has only
been identified in myeloid cell lines and not in cells of lymphoid
Table 2.
Mediator
ELISA analysis of gene secretion induced
by mLITAF overexpression (+/2)*
BLAST SEARCH of the location for the
putative binding sequence, CTCCC.**
TNF-a + 216,220, 285,289, 2155,2159, 2633,2637
MCP-1 + 319,2315, 2298,2294
MCP-2 + 285,289
IL-1a + 340,2344
IL-10 + 2743,2747, 2867,2871
RANTES + 222,226, 290,294, 2138,2142, 2362,2366
IL-6 2 None
IL-1b 2 None
*Raw264.7 cells were transfected with mLITAF or pcDNA alone as control o/n. The secretion protein in the conditioned medium was assessed by ELISA. 200% increase or
more in protein concentration compared to the control was assigned with (+), but it was considered a minus (2) if the protein level was 100% or less than the control.
**Bioinformatic analysis of binding site of TNF-a (U68414), MCP-1 (AL713839), MCP-2 (AL713839), IL-1a (NT_039207.7), IL-10 (HQ014592), RANTES (NT_096135.5), IL-6
(NT_162294.3), or IL-1b (NT_039207.7) in their promoter region from 21t o2900.
doi:10.1371/journal.pone.0025083.t002
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independent authentic mouse gene. While we were unable to
locate this gene in public mouse gene database a possible
explanation may be that the gene could be absent from the
mouse genome assembly. This is consistent with the recently
published information that 1,259 mouse-specific genes were either
missing or grossly misassembled in the mouse genome [22]. More
accurate annotation may be needed.
Aside from the translocation of the transcription factors inside
the nucleus, mSTAT6B functions as an important protein-
binding partner to mLITAF in its ability to induce gene
transcription and protein expression of CCL2. Although Fig. 3a
indicates that mLITAF alone was able to upregulate CCL2
promoter activity, we showed that while mSTAT6B does not
directly bind to CCL2 promoter, it is required for an amplified
regulation of this promoter by mLITAF. We therefore speculate
that the overexpressed mLITAF might interact with endogenous
mSTAT6B in the cytoplasm and translocate into the nucleus as a
protein complex, where mLITAF acts as a CCL2 regulator with
the assistance of mSTAT6B. Furthermore, translocation to
nucleus for other transcription factors such as RelA or CSF-1
was not affected by either mLITAF deficiency or mSTAT6B
gene knock-down in response to LPS suggesting that 1) treatment
of 6BsiRNA1 does not affect RelA or CSF-1 but only mSTAT6B
and 2) either mLITAF deficiency or mSTAT6B knock-down
results in failure of mLITAF/mSTAT6B protein complex to
translocate into the nucleus and mediate the regulation of CCL2
gene expression.
Our data in this study indicates that the critical binding activity
was located in the region of CCL2 59UTR&promoter from 2420
to 2280. Further analysis of this sequence reveled that CTCCC
sequence is found at the repeated region 2319,2315 and
2298,2294. Given that our previous data demonstrated that
CTCCC in the region of TNF-alpha promoter is specific to
LITAF interaction [23], it is very likely that this sequence is also a
regulatory element specific to mLITAF biding activity to other
pro-inflammatory cytokines. Additionally, a bioinformatics anal-
ysis of promoters for classic mediators of inflammation strongly
support the evidence that the presence of CTCCC on their
promoter is consistent with a LITAF biological involvement while
the lack of CTCCC (IL-6) does not show any LITAF biological
involvement.
LPS/TLR2/4/MyD88/p38 MAPK signal transduction gener-
ate the formation of the complex mLITAF/mSTAT6B which
nuclear translocation leads to the transcription of innate immune
response factors such as TNF and CCL2. The knockdown of
mSTAT6B by 6BsiRNA1 prevented mLITAF from regulating
CCL2 production and tail vein injection of 6BsiRNA1 in mice
results in the reduction of LPS-induced serum TNF-a or CCL2
concentration in mice. Furthermore mSTAT6B does not play a
role in the regulation of CCL2 production when mLITAF is
deficient. Our results highlight the important participation of
mLITAF and mSTAT6B in innate immunity suggesting an
important role of STAT6B in TNF and CCL2 mediated diseases.
The role of m6BsiRNA1 is advocated in potential therapeutics for
the treatment of TNF and/or CCL2 diseases.
Figure 3. Effects of mSTAT6B and/or mLITAF on mouse CCL2 59UTR&promoter-enhanced activity. (a) Diagram of DNA deletions of
mouse CCL2 59UTR&promoter region. The PCR-amplified DNA fragment of mouse CCL2 59UTR&promoter in the region from 21034,1, 2840,1,
2560,1, 2420,1, or 2280,1 was respectively inserted into pGL3-basic plasmid as reporter DNAs (named mCL2Pwt, mCL2P840, mCL2P560,
mCL2P420, or mCL1P280). (b) Raw264.7 cells were cotransfected with reporter DNAs of mCL2Pwt, mCL2P840, mCL2P560, mCL2P420 or mCL2P280
plus pcDNA3 as control (white bars), mLITAF (pink bars), mSTAT6B (yellow bars) or both mLITAF&mSTAT6B (blue bars) overnight. All test cells were
cotransfected with 5 ng of b-gal DNA. The lysate from each test cells was assessed by luciferase assay. Triplicate assays were performed and their
values were normalized according to b-gal production and graphed.
doi:10.1371/journal.pone.0025083.g003
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PLoS ONE | www.plosone.org 7 September 2011 | Volume 6 | Issue 9 | e25083Figure 4. Downregulation of CCL2 gene transcription by 6BsiRNA1 silencing of mSTAT6B. (a) Downregulation of CCL2 promoter activity
by 6BsiRNA1. Raw264.7 cells were untreated (No. 1) or transfected with pcDNA3 alone as control (No. 2), mSTAT6B DNA alone (No. 3), 40 nM
m6BsiRNA1 alone (No. 4), 40 nM m6BsiRNA2 alone (No. 5), or cotransfected with mCL2Pwt (No. 6-13) plus pcDNA3 (No. 6), or plus different
concentration of mSTAT6B DNA (No. 7-13). All experimental groups were cotranfsected with 5 ng of b-gal DNA. Treated cells were immediately
added with 6BsiRNA1 (No. 4, 10&11) or 6BsiRNA2 as the negative control (No. 5, 12&13) and cultured overnight. The cell lysate from each test group
was used for luciferase assay. Triplicate assays were performed and their values were normalized according to b-gal production and graphed. (b)
Regulation of CCL2 gene expression by 6BsiRNA1. Raw264.7 cells were transfected with 100 ng pcDNA3 alone as control (white bars), 100 ng
mSTAT6B DNA alone (pink bars), 100 ng mLITAF DNA alone (yellow bars) or cotransfection with both 100 ng mLITAF and 100 ng mSTAT6B DNAs
(blue bars) plus 40 nM 6BsiRNA1 (striped blue bars) or plus 40 nM 6BsiRNA2 as control (dotted blue bars). All test cells were cotransfected with 5 ng
of b-gal DNA. Treated cells were cultured overnight. The conditioned medium from each test group was used to detect CCL2 production by ELISA.
Triplicate assays were performed and their values were normalized according to b-gal production and graphed. (c) Wild-type or LITAF
2/2 mouse
primary macrophages were untreated as control or treated with 100 ng/ml of E. coli LPS for 2 hrs and washed with PBS. The treated cells were added
with different concentrations (20 or 40 nM) of 6BsiRNA1 or 6BsiRNA2 as negative control and cultured overnight. The conditioned medium from each
test group was used to detect CCL2 production by ELISA and the protein concentration of the corresponding cell lysate was measured for
normalization. Triplicate assays were performed and graphed. (d&e) Mouse macrophages collected from wild-type mouse (No. 1-3) or from LITAF-
deficient genotype mice (No. 4-6) were treated with 0.1 mg/ml E. coli LPS (No. 2,3,5&6) or untreated as control (No. 1&4) for 2 hrs and washed with
PBS. The treated cells were cultured overnight. Proteins from whole cells (panel d) or nuclei (panel e) were purified and subjected to Western blot
with the antibodies against mLITAF, mSTAT6B (5287), RelA, CSF-1, or Actin as control (indicated by arrows). The assays were performed in triplicate
and a representative experiment is presented.
doi:10.1371/journal.pone.0025083.g004
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PLoS ONE | www.plosone.org 8 September 2011 | Volume 6 | Issue 9 | e25083Figure 5. Effect of 6BsiRNA1 on LPS-induced serum TNF-a or CCL2 production. Mice (n=666 groups) were treated as shown in Table 1.
Total of 100 ul PBS solution containing 1 mg E. coli LPS plus 40 nM 6BsiRNA2 as control, or plus 20 nM 6BsiRNA1 or 40 nM 6BsiRNA1 was injected
into each mouse. Blood was collected 5 hrs after injection. Mice were warmed under heating lamps to promote blood flow, and a small incision was
made on the tail. About 50 ml of blood was collected per mouse. Red blood cells were removed from the sample via centrifugation at 5,000 rpm for
1 min using serum separator tubes. Top Panel: protein expression from each sample (Nos 1-7) detected by Western blot using antibodies against
mLITAF, 5278 or Actin (control). Lower panel: serum levels of TNF-a (a), CCL2 (b) or IL-1b, IL-6 (c) from each sample measured by ELISA. ELISA
immunoreactivity was quantified using a microplate reader and measurements were graphed. The assays were performed in triplicate and a
representative experiment is presented.
doi:10.1371/journal.pone.0025083.g005
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Figure S1 Identification of mouse mSTAT6B gene. (a)
Diagram of in-frame mSTAT6B cDNA sequence from start to
stop codon (1–564 bp). (b) Northern blot. Filter (Clontech)
containing preblotted mRNAs (2 mg of each) from different mouse
tissues were treated with a a-
32p-dCTP-labeled mouse mSTAT6B
DNA probe (full length size) and an a-
32p-dCTP-labeled mouse
Actin (Amersham Pharmacia, Little Chalfont, UK) as control. The
filter was then autoradiographed with Biomax MR film (Kodak).
The specific hybrids were indicated by arrows. The assays were
done in triplicate and a representative experiment was shown. (c)
Mouse chromosomes fixed on the glass slide were hybridized with
the biotin-labeled mouse mSTAT6B DNA probe (full-length size).
The fluorescent spot, indicated by the arrow, was located on
around chromosome 10q10-13. (d) Western blot detection. 100 mg
lysate from precultured 1610
6 human monocytes (S1, No. 1&3) or
mouse primary macrophages (No. 2&4) was detected by western
blot with the antibody 5278 (recognition site at N-terminus of
mouse mSTAT6B) or STAT6 (recognition site at C-terminus of
human STAT6) as shown at bottom. The detected specific protein
such as human STAT6 (100 kD), human STAT6B (50 kD) or
mouse mSTAT6B (25 kD) was indicated by arrows. The assays
were done in triplicate and the representative experiment was
shown. (e) Analysis of DNA sequence. According to the analysis for
sequence alignment between STAT6 and STAT6B, mouse
mSTAT6B (green box) is highly homologous to human STAT6B
(light coral box) at N terminus, but DNA translation is stopped at
654 bp downstream of C-terminus of human STAT6B. Mouse
mSTAT6B is 89% different from human STAT6 (pink box). The
5278 antibody recognizes the N-terminus of mouse mSTAT6B
(indicated by blank arrow), whereas the STAT6 antibody
recognizes the C-terminus of human STAT6 (gray arrow).
(TIF)
Figure S2 Pull-down assay of mLITAF & mSTAT6B. (a)
The primary macrophages collected from LITAF
2/2 (No. 4&5)
or LITAF
+/+ (No. 1-3) mice were treated with 0.1 mg/ml LPS
(Sigma) of either E. coli (No. 2&4) or P. gingivalis (No. 3&5) or
untreated (No. 1) as the control for 2 hrs and washed with PBS
and cultured overnight. The cell lysate from each test cell was
assessed by Western blot with antibodies against mLITAF,
mSTAT6B or Actin as the control. The assays were done in
triplicate and a representative experiment was shown. (b) The
mouse primary macrophages collected from wild-type mouse
(No. 1-6) or from LITAF-deficient genotype mice (No. 7-12) were
treated with 0.1 mg/ml E. coli LPS (No. 2,4,6,8,10&12) or
untreated as the control (No. 1,3,5,7,9&11) for 2 hrs and washed
with PBS and cultured overnight. The cell lysate from each treated
group was immunoprecipitated (IP) with anti-mLITAF
(No. 3,4,9&10) and anti-mSTAT6 (No. 5,6,11&12). The IP-
proteins were pulled out with protein A/G beads. The precipitates
were subjected to Western blotting with the antibodies against
mSTAT6B (5287), mLITAF or Actin as control (indicated by
arrows). The assays were done in triplicate and a representative
experiment was shown.
(TIF)
Figure S3 Effect of p38 kinase phosphorylation on LPS-
induced mLITAF/mSTAT6B signaling pathway. (a) The
LPS-untreated (No. 1-5) or treated (No. 6-10) mouse primary
macrophages were added with various kinase inhibitors (No. 2&7:
5 mM BAY11-7082 for inhibition of NFkB; No. 3&8: 20 mM H-89
for inhibition of Protein kinase A; No. 4&9: 10 mM U0126 for
inhibition of Protein kinase or MAK/ERK; No. 5&10: 20 mM
SB203580 for inhibition of p38 MAP kinase) and incubated for
3 hrs and washed with PBS. Cells were then cultured overnight.
The whole cell lysate or nuclear protein from each test group was
harvested separately, purified and subjected to Western blot with
antibodies against mLITAF, mSTAT6B (5278) or Actin/tubulin
as the control. The assays were done in triplicate and a
representative experiment was shown. (b) The LPS-untreated
(No. 1-3) or treated (No. 4-6) mouse primary macrophages were
added with two kinase inhibitors (No. 2&5: 10 mM U0126 for
inhibition of Protein kinase or MAK/ERK; 20 mM SB203580 for
inhibition of p38 MAP kinase) and incubated for 3 hrs and washed
with PBS. Cells were then cultured overnight. The whole cell
lysate from each test group was harvested, purified and subjected
to Western blot with antibodies against p-p38, p-NF-kb p65,
pAkt1/2/3 or Actin as the control. The assays were done in
triplicate and the representative experiment was shown.
(TIF)
Information S1
(DOC)
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